ABVC BioPharma, Inc. has received $450,000 in licensing payments from OncoX BioPharma during the third quarter of 2025, including $350,000 received in August. These payments represent continued progress under the companies' strategic licensing agreement that covers four major oncology indications: Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Myelodysplastic Syndromes, and Pancreatic Cancer.
The financial structure of the partnership entitles ABVC to $2,500,000 in cash payments and 5,000,000 OncoX shares, plus future royalties based on net sales. To date, ABVC has received $650,000 in cash payments, with $1,850,000 remaining receivable. When considering ABVC's subsidiary BioLite, the collective entitlement expands to $3.75 million in total cash consideration and 7.5 million OncoX shares, creating a framework with consolidated value exceeding $41 million excluding royalties.
The partnership's significance extends beyond immediate financial gains, as all four oncology indications have received FDA Investigational New Drug approvals, demonstrating ABVC's strong development position in botanical-derived oncology drug candidates. This positions both companies to capitalize on the substantial growth projected in the global cancer therapeutics market, which was valued at approximately $194.67 billion in 2024 and is projected to expand to $469.38 billion by 2034, growing at a compound annual growth rate of 9.2% according to industry research.
Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the execution strength of the collaboration, noting that the payments demonstrate both immediate liquidity and long-term equity value. The partnership reflects a strategic approach to combining innovation with collaboration to create sustainable value in the rapidly expanding oncology therapeutics market. The global cancer therapeutics market valuation and growth projections highlight the substantial commercial opportunity for both companies as they advance their botanical-derived oncology therapeutics toward global commercialization.
